Frederick Locke on Axi-cel and ZUMA-7

Frederick Locke, MD, from Moffitt Cancer Center, shares findings from the ZUMA-7 trial, which evaluated the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in patients with large B-cell lymphoma. Results from the trial were presented at the 2021 American Society of Hematology Annual Meeting.